Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  A. Zang,et al.  Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib , 2020, Scientific Reports.

[3]  Yi-long Wu,et al.  Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Changlian Lu,et al.  Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma , 2020, Journal of Cancer Research and Clinical Oncology.

[5]  Yi-long Wu,et al.  Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases , 2020, JAMA network open.

[6]  Nicholas D. Camarda,et al.  Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma , 2020, Nature Genetics.

[7]  A. Borczuk,et al.  Genomic Underpinnings of Tumor Behavior in in situ and Early Lung Adenocarcinoma. , 2019, American journal of respiratory and critical care medicine.

[8]  M. Catalán,et al.  Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions , 2019, Molecular oncology.

[9]  F. Shepherd,et al.  The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. , 2019, Lung cancer.

[10]  S. Chuai,et al.  Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Publisher's Note , 2018, Anaesthesia.

[12]  Eudocia Q Lee,et al.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study , 2017, Neuro-oncology.

[13]  Xuehua Zhu,et al.  Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[14]  S. Kobayashi,et al.  Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. , 2017, Lung cancer.

[15]  Yi-long Wu,et al.  Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  A. Viale,et al.  Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[18]  J. Pearson,et al.  Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance , 2015, The Journal of pathology.